Remove 2040 Remove Data Remove Programs Remove THC
article thumbnail

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Cannabis Law Report

” The patent provides protection through 2040 and describes use of the Company’s investigational drug ANEB-001 to treat acute cannabinoid overdose. In August Anebulo formed the SAB to advise the Company on its clinical development programs and product pipeline. Condensed Balance Sheet Data. . . and Arjun Chanmugam, M.D.,